Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada

Curr Oncol. 2023 Apr 30;30(5):4663-4676. doi: 10.3390/curroncol30050352.


Background: Many patients with advanced follicular lymphoma (FL) and marginal zone lymphoma (MZL) relapse after first-line chemotherapy.

Objective: To examine healthcare resource utilization (HCRU) and cost, treatment patterns, progression, and survival of patients with FL and MZL who relapse after first-line treatment, in Ontario, Canada.

Methods: A retrospective, administrative data study identified patients with relapsed FL and MZL (1 January 2005-31 December 2018). Patients were followed for up to three years post relapse to assess HCRU, healthcare costs, time to next treatment (TTNT), and overall survival (OS), stratified by first- and second-line treatment.

Results: The study identified 285 FL and 68 MZL cases who relapsed after first-line treatment. Average duration of first-line treatment was 12.4 and 13.4 months for FL and MZL patients, respectively. Drug (35.9%) and cancer clinic costs (28.1%) were major contributors to higher costs in year 1. Three-year OS was 83.9% after FL and 74.2% after MZL relapse. No statistically significant differences were observed in TTNT and OS between patients with FL who received R-CHOP/R-CVP/BR in the first line only versus both the first- and second- line. A total of 31% of FL and 34% of MZL patients progressed to third-line treatment within three years of initial relapse.

Conclusion: Relapsing and remitting nature of FL and MZL in a subset of patients results in substantial burden to patients and the healthcare system.

Keywords: burden of illness; costs; epidemiology; follicular lymphoma; marginal zone lymphoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cost of Illness
  • Humans
  • Lymphoma, B-Cell, Marginal Zone* / drug therapy
  • Lymphoma, B-Cell, Marginal Zone* / epidemiology
  • Lymphoma, B-Cell, Marginal Zone* / pathology
  • Lymphoma, Follicular* / drug therapy
  • Lymphoma, Follicular* / epidemiology
  • Neoplasm Recurrence, Local / epidemiology
  • Ontario / epidemiology
  • Retrospective Studies

Grants and funding

This study was funded by Janssen Inc.